Hummingbird Bioscience was founded in 2014 to develop better ways of generating novel therapeutic antibody-based drugs. Using rational, systems biology approaches the aim of the company is to generate therapeutic antibodies which can be deployed in precision medicine.
To further this goal the company is utilizing cutting edge single cell profiling coupled with expertise in high throughput sequencing, bioinformatics and structural biology to enable our drugs to be used in the right patient at the right time.
The company has 20 employees with operations in JLABS South San Francisco and also in Singapore.
Chief Executive Officer - Piers Ingram, PhD is the Co-Founder and CEO of Hummingbird Bioscience. After completing
undergraduate studies in applied mathematics, Piers completed his PhD in Systems Biology at Imperial College
London, funded by the Wellcome Trust. Piers subsequently held several roles in academia, including as a research group leader at Imperial College, before moving to work in
biopharma R&D consulting and then commercial strategy at Sanofi. Seeing the exciting progress in systems biology and
immunology over the last decade, Piers co-founded Hummingbird Bioscience in 2014 in order to apply these
advances to drug discovery and development. Piers also holds an MBA from INSEAD.
Chief Scientific Officer - Jerome Boyd-Kirkup, PhD is the Co-Founder and Chief Scientific Officer of Hummingbird Bioscience, where he
is responsible for overseeing the development of new technologies and intellectual property and designing
experimental strategies for drug discovery and development. Jerome is a molecular systems biologist by
background with extensive experience in both basic and applied translational science at the interface of
computational and wet lab biology, and a career research focus of applying systems biology approaches to
understanding human disease. Before co-founding Hummingbird Bioscience in 2014, Jerome was an academic
with research experience at top institutions in the UK and China. He holds a Bachelor's and Master's degree in
Biochemistry from Imperial College London and a PhD in Molecular Biology from Cambridge University.
Chief Technology Officer- Konrad Paszkiewicz, PhD overseeing structural biology, computational genomics and transcriptomics, machine learning and internal platform technologies such as mAbPredict and mAbAdvance. He has held several academic positions including Director of the Wellcome Trust Centre for Biomedical Informatics at the University of Exeter, UK and was the head of the University of Exeter Sequencing and Genomics facility. With over 12 years experience in the field, he is an author on over 45 peer reviewed publications and has been an invited speaker and faculty of several renowned scientific workshops and seminar series. He holds an MSci in Physics and a PhD in Bioinformatics from Imperial College, London.
Chief Financial Officer - Sabrina Ng, MBA responsible for overseeing most Business Support functions including Finance, Human Resources, Operations and Fundraising. She has led Hummingbird’s various fund-raising rounds, from angels, institutional investors and government agencies. Prior to Hummingbird, she had extensive cross-border experience advising various FTSE100 and Fortune 500 companies on corporate finance, strategy and change management in her roles at JP Morgan, Greenhill & Co and Bain & Co. She holds a M.A. in Economics from Cambridge University and an MBA from INSEAD.
Board of Directors
In addition to the company founders, Min Cui, PhD and Carl Firth, PhD serve as members of the Board of Directors
Min Cui, PhD is the Founder and Managing Director of Decheng Capital. At Decheng Capital, Dr. Cui has been focusing on partnerships with entrepreneurs and building biotechnology and medical technology companies in China and US. He is currently a board member of AccuraGen, Ariagen, CardioMed, EpimAb Biotherapeutics, GeneMDx, GRAIL, Hummingbird Bioscience, Ketai Medical, Levitas, and SINOMED. Prior to founding Decheng Capital in 2011, Dr. Cui was an Investment Partner at Bay City Capital, a leading international life science venture capital firm in San Francisco. Dr. Cui received his PhD in Cancer Biology from Stanford University and his BS and MS in Molecular Biology from Peking University.
Carl Firth, PhD is Founder and Chief Executive Officer of ASLAN Pharmaceuticals. Prior to founding ASLAN, Carl was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies and advising on M&A transactions. Prior to joining the banking industry, he worked for AstraZeneca across various commercial and R&D roles, including Regional Business Development Director, Asia Pacific, and Director of New Product Development, China. He has a PhD in Molecular Biology from Cambridge University (Trinity College), an Executive MBA from London Business School; and a BA in Molecular Biology from Cambridge University.